Silver bullet against HFpEF remains elusive
13 Nov 2019
byTristan Manalac
Treatment options for patients with heart failure with preserved ejection fraction (HFpEF) remain limited, with benefits that are marginal at best, according to Prof Michel Komajda, past president of the European Society of Cardiology (ESC), at their recently concluded 2019 Asia Congress (ESC Asia 2019).